Company Overview and News

KLCI seen tracking global markets, move between 1,790-1,800

2018-09-11 theedgemarkets
KUALA LUMPUR (Sept 12): The FBM KLCI is seen trading range bound today, and move between the 1,790 and 1,800-levels, in line with the overnight gains at most global markets.
5249 0145 5049 BRDBF 5210 0075

IOI Properties, AirAsia, Bumi Armada, Country View, CCM, Sunsuria, TDM, Serba Dinamik, TFP and Mexter

2018-09-07 theedgemarkets
KUALA LUMPUR (July 5): Based on corporate announcements and news flow today, companies in focus on Wednesday (Sept 12) may include: IOI Properties Group Bhd, AirAsia Group Bhd, Bumi Armada Bhd, Country View Bhd, Chemical Company of Malaysia Bhd, Sunsuria Bhd, TDM Bhd, Serba Dinamik Holdings Bhd, TFP Solutions Bhd and Mexter Technology Bhd.
5249 0145 5049 BRDBF BSMAF 5210 0075 1818

TFP Solutions disposes stake in Bangladesh JV

2018-09-07 theedgemarkets
KUALA LUMPUR (Sept 7): TFP Solutions Bhd is pulling out of its Bangladesh solution business joint venture, due to “irreconcilable differences and incompatibility” with its partner.
0145 BSMAF 1818

TFP Solutions down 8% on share capital reduction plan

2018-09-07 theedgemarkets
KUALA LUMPUR (Sept 7): Loss-making TFP Solutions Bhd fell 8% this morning after it proposed to undertake a reduction of its issued share capital, which will give rise to a credit of RM17.5 million, to reduce its accumulated losses and enhance its credibility with customers, suppliers and investors.

KLCI seen under pressure, to track global markets

2018-09-06 theedgemarkets
KUALA LUMPUR (Sept 7): The FBM KLCI seen under pressure today, in line with the overnight decline at most global markets.
0154 5347 5115 0145 9296 TNABY 0107 TNABF 7123

Priceworth, TFP Solutions, TNB, FGV, Alam Maritim, MMC Corp, iDimension, Eduspec, RCE Capital and EA Holdings

2018-09-06 theedgemarkets
KUALA LUMPUR (Sept 6): Based on corporate announcements and news flow today, companies that may be in focus tomorrow (Sept 7) may include the following: Priceworth International Bhd, TFP Solutions Bhd, Tenaga Nasional Bhd, FGV Holdings Bhd, Alam Maritim Resources Bhd, MMC Corp Bhd, iDimension Consolidated Bhd, Eduspec Holdings Bhd, RCE Capital Bhd and EA Holdings Bhd.
0154 5347 5115 0145 9296 TNABY 0107 RCL TNABF BSMAF 7123 1818

DBE Gurney, KLCC Stapled Group, Salcon, TFP Solutions, Pasdec, GHL Systems, Nova MSC and Xinghe

2018-07-16 theedgemarkets
KUALA LUMPUR (July 16): Based on corporate announcements and news flow today, companies that may be in focus on Tuesday (July 17) may include the following: DBE Gurney Resources Bhd, KLCC Stapled Group, Salcon Bhd, TFP Solutions Bhd, Pasdec Holdings Bhd, GHL Systems Bhd, Nova MSC Bhd and Xinghe Holdings Bhd.
6912 0145 0026 BSMAF 0095 0021 1818

TFP's major shareholder Hussian now its MD

2018-07-16 theedgemarkets
KUALA LUMPUR (July 16): TFP Solutions Bhd's major shareholder Datuk Hussian @ Rizal A. Rahman, 56, is now its managing director effective today.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...